Recombinant vesiculoviruses and their uses
CA 2220133 C · Owner: Yale University · Inventors: Rose, John K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time successfully allows the , production and recovery of replicable vesiculoviruses as well as recombinant , replicable vesiculoviruses from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers and have use as vaccines. The , recombinant vesiculoviruses can also be inactivated for use as killed vaccines.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 1, 1996 and granted July 5, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 1, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 1, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.